Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.
At a glance
- EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004) et al.
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010) et al.
- ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin Oncol. 30, 863–870 (2012) et al.
- Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 3, 630–635 (2013) et al.
- Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004) et al.
- p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491–494 (1989) et al.
- Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659–3662 (2002) et al.
- Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 55, 505–509 (1995) et al.
- Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420 (2006) et al.
- Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum. Mutat. 29, 617–622 (2008) et al.
- Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008) et al.
- Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012) et al.
- Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121–1134 (2012) et al.
- New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J. Clin. Oncol. 31, 992–1001 (2013) , &
- Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012)
- Absolute quantification of somatic DNA alterations in human cancer. Nature Biotechnol. 30, 413–421 (2012) et al.
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol. 31, 213–219 (2013) et al.
- Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014) et al.
- Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif. EMBO J. 18, 7019–7028 (1999) , , , &
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genet. 44, 1104–1110 (2012) et al.
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genet. 44, 1111–1116 (2012) et al.
- The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11, 1167–1173 (2005) et al.
- A novel gene, DXS8237E, lies within 20 kb upstream of UBE1 in Xp11.23 and has a different X inactivation status. Genomics 31, 135–138 (1996) et al.
- Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893–898 (2007) et al.
- Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011) et al.
- Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res. 66, 283–289 (2006) et al.
- The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109–2119 (2012) et al.
- Functional recognition of the 3′ splice site AG by the splicing factor U2AF35. Nature 402, 832–835 (1999) , , &
- A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS ONE 9, e87361 (2014) et al.
- Chipping away at the lung cancer genome. Nature Med. 18, 349–351 (2012) &
- Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007–20012 (2007) et al.
- Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene http://dx.doi.org/10.1038/onc.2013.581 (2014) et al.
- Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 12, R40 (2010) et al.
- Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS ONE 7, e36530 (2012) et al.
- Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Med. 8, 816–824 (2002) et al.
- Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24, 5079–5090 (2006) et al.
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790–13795 (2001) et al.
- International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thoracic Oncol. 6, 244–285 (2011) et al.
- TTF-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol. 26, 767–773 (2002) , &
- Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 33, 1277–1285 (2012) et al.
- Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc. Natl Acad. Sci. USA 110, 4245–4250 (2013) et al.
- Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013) et al.